» Articles » PMID: 28532504

Vineland Adaptive Behavior Scales to Identify Neurodevelopmental Problems in Children with Congenital Hyperinsulinism (CHI)

Overview
Publisher Biomed Central
Specialty General Medicine
Date 2017 May 24
PMID 28532504
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Congenital Hyperinsulinism (CHI) is a disease of severe hypoglycaemia caused by excess insulin secretion and associated with adverse neurodevelopment in a third of children. The Vineland Adaptive Behavior Scales Second Edition (VABS-II) is a parent report measure of adaptive functioning that could be used as a developmental screening tool in patients with CHI. We have investigated the performance of VABS-II as a screening tool to identify developmental delay in a relatively large cohort of children with CHI. VABS-II questionnaires testing communication, daily living skills, social skills, motor skills and behaviour domains were completed by parents of 64 children with CHI, presenting both in the early neonatal period (Early-CHI, n = 48) and later in infancy (Late-CHI, n = 16). Individual and adaptive composite (Total) domain scores were converted to standard deviation scores (SDS). VABS-II scores were tested for correlation with objective developmental assessment reported separately by developmental paediatricians, clinical and educational psychologists. VABS-II scores were also investigated for correlation with the timing of hypoglycaemia, gender and phenotype of CHI.

Results: Median (range) total VABS-II SDS was low in CHI [-0.48 (-3.60, 4.00)] with scores < -2.0 SDS in 9 (12%) children. VABS-II Total scores correctly identified developmental delay diagnosed by objective assessment in the majority [odds ratio (OR) (95% confidence intervals, CI) 0.52 (0.38, 0.73), p < 0.001] with 95% specificity [area under curve (CI) 0.80 (0.68, 0.90), p < 0.001] for cut-off < -2.0 SDS, although with low sensitivity (26%). VABS-II Total scores were inversely correlated (adjusted R = 0.19, p = 0.001) with age at presentation (p = 0.024) and male gender (p = 0.036), males having lower scores than females in those with Late-CHI [-1.40 (-3.60, 0.87) v 0.20 (-1.07, 1.27), p = 0.014]. The presence of a genetic mutation representing severe CHI also predicted lower scores (R = 0.19, p = 0.039).

Conclusions: The parent report VABS-II is a reliable and specific tool to identify developmental delay in CHI patients. Male gender, later age at presentation and severity of disease are independent risk factors for lower VABS-II scores.

Citing Articles

Standardised practices in the networked management of congenital hyperinsulinism: a UK national collaborative consensus.

Shaikh M, Lucas-Herald A, Dastamani A, Estebanez M, Senniappan S, Abid N Front Endocrinol (Lausanne). 2023; 14:1231043.

PMID: 38027197 PMC: 10646160. DOI: 10.3389/fendo.2023.1231043.


Psychometric outcome measures in beta-propeller protein-associated neurodegeneration (BPAN).

Gavazzi F, Pierce S, Vithayathil J, Cunningham K, Anderson K, McCann J Mol Genet Metab. 2022; 137(1-2):26-32.

PMID: 35878504 PMC: 9613602. DOI: 10.1016/j.ymgme.2022.07.009.


Congenital hyperinsulinism in infancy and childhood: challenges, unmet needs and the perspective of patients and families.

Banerjee I, Raskin J, Arnoux J, De Leon D, Weinzimer S, Hammer M Orphanet J Rare Dis. 2022; 17(1):61.

PMID: 35183224 PMC: 8858501. DOI: 10.1186/s13023-022-02214-y.


Correlation between 2D and 3D Fetal Brain MRI Biometry and Neurodevelopmental Outcomes in Fetuses with Suspected Microcephaly and Macrocephaly.

Fried S, Gafner M, Jeddah D, Gosher N, Hoffman D, Ber R AJNR Am J Neuroradiol. 2021; 42(10):1878-1883.

PMID: 34385141 PMC: 8562748. DOI: 10.3174/ajnr.A7225.


Long-Term Outcome and Treatment in Persistent and Transient Congenital Hyperinsulinism: A Finnish Population-Based Study.

Mannisto J, Jaaskelainen J, Otonkoski T, Huopio H J Clin Endocrinol Metab. 2021; 106(4):e1542-e1551.

PMID: 33475139 PMC: 7993590. DOI: 10.1210/clinem/dgab024.


References
1.
Arnoux J, Verkarre V, Saint-Martin C, Montravers F, Brassier A, Valayannopoulos V . Congenital hyperinsulinism: current trends in diagnosis and therapy. Orphanet J Rare Dis. 2011; 6:63. PMC: 3199232. DOI: 10.1186/1750-1172-6-63. View

2.
Meissner T, Wendel U, Burgard P, Schaetzle S, Mayatepek E . Long-term follow-up of 114 patients with congenital hyperinsulinism. Eur J Endocrinol. 2003; 149(1):43-51. DOI: 10.1530/eje.0.1490043. View

3.
Banerjee I, Skae M, Flanagan S, Rigby L, Patel L, Didi M . The contribution of rapid KATP channel gene mutation analysis to the clinical management of children with congenital hyperinsulinism. Eur J Endocrinol. 2011; 164(5):733-40. DOI: 10.1530/EJE-10-1136. View

4.
Hack M . Consideration of the use of health status, functional outcome, and quality-of-life to monitor neonatal intensive care practice. Pediatrics. 1999; 103(1 Suppl E):319-28. View

5.
De Leon D, Stanley C . Mechanisms of Disease: advances in diagnosis and treatment of hyperinsulinism in neonates. Nat Clin Pract Endocrinol Metab. 2006; 3(1):57-68. DOI: 10.1038/ncpendmet0368. View